Ariad Pharmaceuticals Inc fka ARIA

[BTH]

Of course that doesn't stop you from parsing my words and leaving out the "sarcoma" part of it, right?

the "limited" efficacy they show, as well as almost never mentioning "robust" data in sarcoma for mTORs

Oh, and not only that, but, you can certainly have a "best in class" among a poor group. In this case, Afinitor certainly is "best in class", not ridaforolimus despite the garbage shareholders have been fed thus far from Ariad. Afinitor is being used in conjunction with other drugs, in many indications - as I've said, combo is the way mTORs will show a sustained efficacy - as I've pointed out in several medical abstracts.